ClinicalTrials.gg
Drug

Azelastine clinical trials

studies test it
31
open now
2
in phase 3
15
first study started
2005

Counted the way a researcher would: Azelastine with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.

This browser remembers your choice.

How each study uses azelastine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the azelastine studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
1 Nov 1996 · ASTELIN · NDA 020114 (FDA, Drugs@FDA)
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

0.15% azelastine hydrochloride
4
Azelastine
3
Astepro 0.15%
3
azelastine hydrochloride
2

In one entry with another drug

Given together, or one or the other

Azelastine, Fluticasone
2
azelastine hydrochloride and fluticasone propionate
2
azelastine Hcl/fluticasone propionate
2

Studies by the year they started

31 studies that test it; most in 2007 (5)

Studies that test azelastine, by start year
YearStudies
20051
20062
20075
20084
20092
20103
20111
20131
20142
20151
20171
20202
20222
20234

By phase

A phase 1/2 study counts in both.

Phase 1
4
Phase 2
3
Phase 3
15
Phase 4
7
No phase
2

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 24 · Other 7

Meda Pharmaceuticals (11) · MEDA Pharma GmbH & Co. KG (4) · University of Chicago (3) · Sandoz (2) · Humanis Saglık Anonim Sirketi (1) · Bayer (1) · AstraZeneca (1) · Hanlim Pharm. Co., Ltd. (1)

Often tested with

Tested in the same studies.

Fluticasone (11) · Mometasone Furoate (5) · Ciclesonide (1) · Budesonide (1) · Gsk-256066 (1) · Montelukast (1)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 1

Studies that test azelastine.

Studies

Open first, then newest update. How each study uses azelastine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 31

See all 31 studies that test azelastine →

Given beside what is tested · 1 — azelastine is usual care or a partner of the new treatment
As the comparator · 9 — what is tested is compared with azelastine

Codes

What other systems call azelastine · ClinicalTrials.gg INT002735

  • MeSH (NLM) C020976azelastineConfirmed ClinicalTrials.gov, NLM, Wikidata
  • UNII (FDA) ZQI909440XAZELASTINEConfirmed FDA, NLM, Wikidata
  • RxNorm 18603Confirmed FDA, Wikidata
  • Wikidata Q419820azelastineConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C61643AzelastineOne source FDA
  • DrugBank DB00972One source Wikidata

Also registered as azelastine hydrochloride (UNII 0L591QR10I · RxNorm 235824).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.